Enhancing Diabetic Nephropathy Treatment: Beyond RAS Blockade

Feb 26, 2025

10 likes | 82 Views

Explore clinical trials on add-on therapies to RAS blockade in Diabetic Kidney Disease. Learn about novel approaches for diabetic nephropathy management.

Share Presentation

Embed Code

Link

ras blockade
diabetic nephropathy
clinical trials
addon therapies
therapeutic approaches

randall-baxter

Download Presentation

Enhancing Diabetic Nephropathy Treatment: Beyond RAS Blockade

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Table 1 Clinical trials of add-on therapies to RAS blockade in DKD Fernandez-Fernandez, B. et al. (2014) Therapeutic approaches to diabetic nephropathy—beyond the RAS Nat. Rev. Nephrol. doi:10.1038/nrneph.2014.74

RAS blockade in the real world: Clinical lessons from recent trials

Cardio Diabetes Master Class Asian chapter January 28-30 2011, Shanghai. Presentation topic. RAS blockade in the real world: Clinical lessons from recent trials. Slide lecture prepared and held by:. Sverre Kjeldsen, MD Ullevaal University Hospital Oslo, Norway.

759 views • 33 slides

Clinical Trials 1

Clinical Trials 1. Darlene Kitterman, MBA, Director, Investigator Support & Integration Services (ISIS), Oregon Clinical & Translational Research Institute (OCTRI). Audience.

497 views • 26 slides

Add to table of Contents:

Add to table of Contents:. Wildlife Refuge Pg. 16 Dimensional analysis Pg . 17. Dimensional Analysis. Dimensional Analysis. Many problems in chemistry involve using relationships to convert one unit of measurement to another. Conversion factors are relationships between two units.

251 views • 8 slides

Phase 1 Clinical Trials

summary

1.99k views • 29 slides

Clinical trials (1)

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s P rogrammes at the University of Pécs and at the University of Debrecen Identification number : TÁMOP-4.1.2-08/1/A-2009-0011.

346 views • 26 slides

Table 3 Immunotherapy in clinical trials for glioblastoma

Table 3 Immunotherapy in clinical trials for glioblastoma. Tanaka, S. et al . ( 2012) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.204.

300 views • 1 slides

Table 2 Molecular-targeted therapies in clinical trials

Table 2 Molecular-targeted therapies in clinical trials. Tanaka, S. et al . ( 2012) Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.204.

149 views • 1 slides

Clinical evaluation of CB 1 receptor blockade

Clinical evaluation of CB 1 receptor blockade. Rimonabant clinical trial program. Rimonabant In Obesity (RIO) program. Randomized, double-blind, placebo-controlled trials.

271 views • 14 slides

Table 1 Timing of clinical trials and FDA approval for selected targeted therapies

Table 1 Timing of clinical trials and FDA approval for selected targeted therapies. Maxwell, K. N. & Domchek, S. M. ( 2012) Cancer treatment according to BRCA1 and BRCA2 mutations Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.123.

191 views • 1 slides

Table 1 Ongoing clinical trials of passive Aβ immunotherapies

Table 1 Ongoing clinical trials of passive Aβ immunotherapies. Lemere, C. A. & Masliah, E. (2010) Can Alzheimer disease be prevented by amyloid‑β immunotherapy? Nat. Rev. Neurol. doi:10.1038/nrneurol.2009.219.

131 views • 1 slides

Table 1 An overview of key clinical trials of afatinib in lung cancer

Table 1 An overview of key clinical trials of afatinib in lung cancer. Yu, H. A. & Pao, W. ( 2013) Afatinib—new therapy option for EGFR-mutant lung cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2013.154.

172 views • 1 slides

Table 1 Clinical trials on AAV

Table 1 Clinical trials on AAV. Chen, M. & Kallenberg, C. G. M. (2010) ANCA-associated vasculitides—advances in pathogenesis and treatment Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2010.158.

152 views • 1 slides

Clinical evaluation of CB 1 receptor blockade

Clinical evaluation of CB 1 receptor blockade. Rimonabant clinical trial program. Rimonabant In Obesity (RIO) program. Randomized, double-blind, placebo-controlled trials.

152 views • 14 slides

Add to table of contents:

Add to table of contents:. Soil Horizons Pg. 70 Soil Pg. 71. Observing Soil - What do you see?. Soil Pg. 71. Soil is a mixture of four materials:. Soil Pg. 71. Soil is a mixture of four materials: Weathered rock particles-45%. Soil Pg. 71.

246 views • 23 slides

RAS blockade in the real world: Clinical lessons from recent trials

348 views • 33 slides

Add to Table of contents:

Add to Table of contents:. Lab Safety Wkst Pg. 2 Lab Safety Pg. 3. Interactive Notebook (INB) Set-Up. First, number pages front and back, starting with the very first page(Table of Contents)as #1. Put numbers on top outside corner, away from the spiral. Even #. Odd #.

108 views • 9 slides

Add to Table of contents:

Add to Table of contents:. Lab Safety Wkst Pg. 2 Lab Safety Pg. 3. Interactive Notebook (INB) Set-Up. First, number pages front and back, starting with the very first page as #1. Put numbers on top outside corner, away from the spiral. Even #. Odd #.

93 views • 8 slides

Add to table of Contents:

Add to table of Contents:. Karyotype Example Pg. 56 Karyotypes Pg. 57. Review: Humans have ___ pairs, ____ (total)chromosomes. The last pair is the sex chromosomes. 23. XX = XY =. 46. girl. boy. X. Y. X. X.

434 views • 42 slides

More Related